Home / Stocks / VRTX

Vertex Pharmaceuticals (VRTX, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

Vertex Pharmaceuticals (VRTX, Biotechnology) trades at a blended P/E of 28.9, about 55% below its historical normal valuation, with a forward growth estimate of 14.4% and a PEG of 2.01. Analysts' one-year estimates have been hit 36% of the time.

DATA AS OF 2026-08-21
Blended P/E
28.9
Normal P/E
64.0
PEG
2.01
Fwd growth
14.4%
Div yield
0.0%
RSI (14)
64.9
Neutral

The Street vs SeerForecast

Wall Street's mean price target for VRTX is $563.12 across 25 analysts, 2.7% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from trading above fair value (2026-06-03) to significantly overvalued (2026-08-21).

Price and rating by weekClose moved +18.1 percent from 2026-06-03 to 2026-08-17, with 3 rating changes over 21 recorded weeks.2026-06-03: Trading above fair value, close 428.34 (recalculated)2026-06-10: Trading above fair value, close 435.71 (recalculated)2026-06-14: Trading above fair value, close 444.93 (recalculated)2026-06-16: Trading above fair value, close 453.17 (recalculated)2026-06-21: Trading above fair value, close 451.63 (recalculated)2026-07-02: Significantly overvalued, close 528.04 (recalculated)2026-07-06: Significantly overvalued, close 529.59 (recalculated)2026-07-09: Significantly overvalued, close 496.50 (recalculated)2026-07-12: Trading above fair value, close 485.39 (recalculated)2026-07-13: Trading above fair value, close 480.25 (recalculated)2026-07-14: Trading above fair value, close 476.31 (recalculated)2026-07-20: Trading above fair value, close 480.50 (recalculated)2026-07-22: Trading above fair value, close 472.57 (recalculated)2026-07-25: Trading above fair value, close 477.36 (recalculated)2026-07-27: Trading above fair value, close 479.00 (recalculated)2026-07-31: Trading above fair value, close 477.10 (recalculated)2026-08-03: Trading above fair value, close 477.102026-08-07: Trading above fair value, close 496.07 (recalculated)2026-08-10: Significantly overvalued, close 496.072026-08-14: Significantly overvalued, close 505.75 (recalculated)2026-08-17: Significantly overvalued, close 505.754285062026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 24.0-63%Trading above fair value
2026-06-10P/E 23.9-63%Trading above fair value
2026-06-14P/E 23.9-63%Trading above fair value
2026-06-16P/E 23.9-63%Trading above fair value
2026-06-21P/E 23.9-63%Trading above fair value
2026-07-02P/E 26.6-58%Significantly overvalued
2026-07-06P/E 28.2-56%Significantly overvalued
2026-07-09P/E 28.2-56%Significantly overvalued
2026-07-12P/E 25.9-60%Trading above fair value
2026-07-13P/E 25.9-60%Trading above fair value
2026-07-14P/E 25.9-60%Trading above fair value
2026-07-20P/E 25.9-60%Trading above fair value
2026-07-22P/E 25.9-60%Trading above fair value
2026-07-25P/E 25.4-60%Trading above fair value
2026-07-27P/E 25.4-60%Trading above fair value
2026-07-31P/E 25.6-60%Trading above fair value
2026-08-03P/E 25.4-60%Trading above fair value
2026-08-07P/E 25.9-60%Trading above fair value
2026-08-10P/E 26.5-59%Significantly overvalued
2026-08-14P/E 27.6-57%Significantly overvalued
2026-08-17P/E 27.1-58%Significantly overvalued
2026-08-21P/E 28.9-55%Significantly overvalued ← now

Frequently asked questions

Is Vertex Pharmaceuticals stock overvalued?

At a blended P/E of 28.9 versus its historical normal P/E of 64.0, Vertex Pharmaceuticals trades about 55% below its typical valuation, with a PEG of 2.01 on 14.4% forward growth. tickerseer currently rates it significantly overvalued.

What is Vertex Pharmaceuticals's fair value and PEG?

Vertex Pharmaceuticals trades at a blended P/E of 28.9 against a historical normal P/E of 64.0, a PEG of 2.01, and a forward growth estimate of 14.4%.

Has tickerseer's rating of Vertex Pharmaceuticals changed?

tickerseer's rating moved from trading above fair value (2026-06-03) to significantly overvalued (2026-08-21).

What is the analyst price target for Vertex Pharmaceuticals?

The mean Wall Street price target for Vertex Pharmaceuticals is $563.12 across 25 analysts, 2.7% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track VRTX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.